초록 ▼

Liquid polyoxaester polymer materials are provided as suspending vehicles suitable for dispensing of pharmaceutically active agents, such as proteins, from delivery devices, for example, pump-driven dosage forms. Polyoxaesters are made from at least one diacid and at least one diol. Through the use

Liquid polyoxaester polymer materials are provided as suspending vehicles suitable for dispensing of pharmaceutically active agents, such as proteins, from delivery devices, for example, pump-driven dosage forms. Polyoxaesters are made from at least one diacid and at least one diol. Through the use of polyoxaesters virtually solvent-free pharmaceutical suspensions can be created.

대표청구항 ▼

1. An implantable osmotic dosage form comprising: a pharmaceutical suspension comprising (i) particles comprising a protein or peptide, and (ii) a suspending vehicle comprising a polyoxaester having a density of about 1.2 g/mL, wherein the pharmaceutical suspension is substantially homogeneous for a

1. An implantable osmotic dosage form comprising: a pharmaceutical suspension comprising (i) particles comprising a protein or peptide, and (ii) a suspending vehicle comprising a polyoxaester having a density of about 1.2 g/mL, wherein the pharmaceutical suspension is substantially homogeneous for at least 3 months at 37° C.;a first wall that maintains its physical and chemical integrity and is substantially impermeable to a pharmaceutical suspension;a second wall that is partially permeable to an exterior fluid;an osmotic pump in contact with the first wall and the second wall;a compartment defined by the first wall and the osmotic pump, wherein the pharmaceutical suspension is positioned within the compartment; andan exit port in communication with the compartment, wherein the pharmaceutical suspension is flowable through the exit port under a force exerted by the osmotic pump. 2. A method of making the dosage form of claim 1 comprising, loading the pharmaceutical suspension into the compartment. 3. The dosage form of claim 1, wherein the pharmaceutical suspension is substantially free of solvents. 4. The dosage form of claim 1, wherein the polyoxaester comprises reaction products of at least one diacid and at least one diol. 5. The dosage form of claim 4, wherein the diacid is selected from the group consisting of a polyglycolic diacid; a 3,6-trioxaundecanedioic diacid; a 3,6,9-trioxaundecanedioic diacid; and combinations thereof. 6. The dosage form of claim 4, wherein the diol is selected from the group consisting of an ethyleneglycol, a propanediol, a butanediol, a pentanediol, a cyclopentanediol, a hexanediol, a cyclohexanediol, an octanediol, a decanediol, a dodecanediol, a cyclohexanedimethanol, a polyethyleneglycol, a polypropyleneglycol, and combinations thereof. 7. The dosage form of claim 1, wherein the polyoxaester comprises condensation products of a mixture comprising a polyglycolic diacid and an ethyleneglycol. 8. The dosage form of claim 7, wherein the mixture further comprises a 3,6,9-trioxaundecanedioic diacid. 9. The dosage form of claim 7, wherein the polyoxaester has a molecular weight of from approximately 1,000 to approximately 100,000. 10. The dosage form of claim 1, wherein the polyoxaester comprises condensation products of a mixture comprising a 3,6,9-trioxaundecanedioic diacid and an ethyleneglycol. 11. The dosage form of claim 10, wherein the polyoxaester has a molecular weight of from approximately 1,000 to approximately 100,000. 12. The dosage form of claim 1, wherein the suspending vehicle consists essentially of the polyoxaester. 13. The dosage form of claim 1, wherein the osmotic pump comprises a piston and a fluid-imbibing agent. 14. The dosage form of claim 1, wherein the pharmaceutical suspension is substantially homogeneous for at least 6 months. 15. The dosage form of claim 1, wherein the pharmaceutical suspension is substantially homogeneous for at least 1 year. 16. The dosage form of claim 1, wherein the pharmaceutical suspension comprises from about 0.1% to about 30% of particles by weight. 17. The dosage form of claim 1, wherein the pharmaceutical suspension comprises from about 0.5% to about 15% of particles by weight.